about
Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patientsThe use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenograftsThe impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitorClinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in GlioblastomaSingle agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells.Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro.Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.Targeting glioma stem-like cell survival and chemo-resistance through inhibition of lysine-specific histone demethylase KDM2B.Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma.Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas.Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility studyVEGF-C as a putative therapeutic target in cancer
P50
Q33576750-54193346-B900-4D97-90B6-4FC45DBAD57CQ33740417-FB4B42EC-520C-4CF0-9224-032112040E7EQ34293163-EC52E077-DDBB-4B40-9F17-C1A361C659ADQ34452854-F415D1F7-F1F0-4A85-9F1D-FB4F51AF8704Q34978253-EEA45523-1696-4976-BCD8-D6135AAF72A7Q35094941-5192CAB0-E8AA-46D2-896C-AF293B5C0796Q36648767-6D6BFF79-8AC6-4777-AA7A-0FC47FDFC6F5Q39350206-C2492701-5020-4DDF-8540-9031EDEB6160Q39818316-685042D3-897E-4908-82B0-9A19B6735C28Q40939911-C1EBBFEE-3D57-45C0-8B35-3606B8C35DFCQ47845301-0A4F4CBB-61AF-4214-8653-6F58C2B6AD19Q48299999-34A8C08B-23B8-4148-97C0-08ADE6D6CDFEQ48872466-635F0E56-5EF9-4D12-9233-FB48E91F3CF0Q49377197-1D30F0B0-DB67-4D07-9087-F055B20F75AAQ51757810-E1C59221-CAC3-45AA-A990-94FA9810E381Q52148559-3B575E00-61E8-4091-9DE1-8474ECA604E6Q52679029-FEF4FDDA-76B9-42A4-9AFF-EA2E5DF4C2BDQ92005579-134A23AF-8175-4CBD-B06F-0DD1863AD203Q93149517-DE180C6C-5F3D-4432-A908-32E49DF771B7
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Signe Regner Michaelsen
@ast
Signe Regner Michaelsen
@en
Signe Regner Michaelsen
@es
Signe Regner Michaelsen
@nl
Signe Regner Michaelsen
@sl
type
label
Signe Regner Michaelsen
@ast
Signe Regner Michaelsen
@en
Signe Regner Michaelsen
@es
Signe Regner Michaelsen
@nl
Signe Regner Michaelsen
@sl
prefLabel
Signe Regner Michaelsen
@ast
Signe Regner Michaelsen
@en
Signe Regner Michaelsen
@es
Signe Regner Michaelsen
@nl
Signe Regner Michaelsen
@sl
P106
P21
P31
P496
0000-0001-9047-6384